Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818070) titled 'A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma' on Sept. 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Ono Pharmaceutical Co., Ltd.
Condition:
Gastric Cancer
Esophagogastric Junction Cancer
Esophageal Adenocarcinoma
Intervention:
Drug: ONO-4578
Other: Placebo
Drug: Nivolumab
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Tegafur-gim...